Atterocor is a drug development company focused on the accelerated development of a novel treatment for adrenal cancer,
a rare endocrine cancer.

Learn More

November 12, 2014
Atterocor Appoints Pharis Mohideen, M.D., as Chief Medical Officer Read More >>

June 12, 2014
Atterocor Announces Data Presentations at ICE/ENDO 2014 Read More >>